[ORGANIZATION]
The Lancet Diabetes & Endocrinology
Featured in 5 tracked stories · first seen
Situations
GLP-1 drugs: clinical trends, safety, and market shifts
256 clusters · 928 sources · last updated
Latest: GLP-1 medications linked to reduced food cravings and unreported side effects
Since mid-2026, the expansion of GLP-1 agents for obesity has been accompanied by intensified safety monitoring and evolving clinical data. Research suggests secondary benefits, including a 21% lower risk of fragility fr
Prenatal DEHP exposure and neurodevelopmental risks
2 clusters · 4 sources · last updated
Latest: DEHP plasticizer exposure linked to autism and ADHD symptoms
Research published in the journal Med has identified an association between prenatal exposure to DEHP—a plasticizer used to increase the flexibility of materials like PVC—and an increased presence of symptoms related to
Obesity drug advances and health assessment
5 clusters · 23 sources · last updated
Latest: Mexico approves oral semaglutide for weight management
A July 22 review of 262 randomized trials involving nearly 100,000 adults found that the newest anti‑obesity medicines—particularly tirzepatide and semaglutide—produce the greatest weight loss but also raise rates of gas